Mink Therapeutics Inc's Comment on Sales, Marketing and Customers
The company operates in markets related to healthcare products governed by various federal and state anti-bribery, fraud, abuse, and healthcare laws and regulations. Its market segments include federal and state healthcare programs such as Medicare and Medicaid. Customers include physicians—defined as doctors, dentists, optometrists, podiatrists, and chiropractors—teaching hospitals, and other healthcare providers such as physician assistants and nurse practitioners. Additionally, manufacturers of covered drugs, devices, biologics, and medical supplies reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program are required to report payments and transfers of value to these healthcare providers under the Physician Payments Sunshine Act.
In a significant advancement in cancer treatment, MiNK Therapeutics, Inc. (NASDAQ: INKT), a pioneering clinical-stage biopharmaceutical company, showcased its innovative approach to tackling advanced gastroesophageal cancers at the esteemed American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium held in San Francisco, California. The company is committed to transforming the landscape of cancer therapy through the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, aimed at reconstituting the immune system in patients battling these formidable malignancies.At the ASCO GI Symposium, MiNK Therapeutics presented a novel combination therapy that me...
MiNK Therapeutics Presents Promising Clinical Activity of AgenT-797 in Severe Acute Respiratory Distress Syndrome (ARDS) and Gastric Cancer PatientsNew York, May 22, 2024 - MiNK Therapeutics, Inc. (NASDAQ: INKT), a leading clinical-stage biopharmaceutical company specializing in allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, revealed new clinical data regarding agenT-797 at the American Thoracic Society (ATS) Annual Meeting. The findings presented shed light on the drug s efficacy in a complex case of severe ARDS, augmenting the growing body of evidence demonstrating its clinical activity in patients with severe ARDS.MiNK Therapeutic...
MiNK Therapeutics, a clinical-stage biopharmaceutical company, recently announced the initiation of a Phase 2 investigator sponsored study for agenT-797 in second line gastroesophageal cancer. Led by Dr. Yelena Janjigian at the Memorial Sloan Kettering Cancer Center, this study aims to build upon the remarkable findings from MiNK s previous clinical trial, demonstrating the potential of agenT-797 in overcoming resistance to immune checkpoint inhibitors (ICIs) in patients with chemotherapy and anti-PD-1 refractory gastric cancer.AgenT-797: A Potential Game-Changer:In a case report published in Oncogene, MiNK Therapeutics heralds the efficacy of agenT-797 in their phase 1/2 study involving patients with advanc...
:This article discusses the groundbreaking findings of a case report published in Oncogene by MiNK Therapeutics, Inc. The study highlights the potential of MiNK s allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapy, agenT-797, to overcome resistance to immune checkpoint inhibitors (ICIs) in treating advanced solid tumors, specifically gastric cancer refractory to anti-PD1 therapy. The study demonstrates a durable partial response in a patient after a single infusion of agenT-797. This breakthrough offers hope for patients who have not responded well to traditional ICI treatments.MiNK Therapeutics, a clinical-stage biopharmaceutical company, has recently published a case report in Oncoge...
Mink Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company operates in markets related to healthcare products governed by various federal and state anti-bribery, fraud, abuse, and healthcare laws and regulations. Its market segments include federal and state healthcare programs such as Medicare and Medicaid. Customers include physicians—defined as doctors, dentists, optometrists, podiatrists, and chiropractors—teaching hospitals, and other healthcare providers such as physician assistants and nurse practitioners. Additionally, manufacturers of covered drugs, devices, biologics, and medical supplies reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program are required to report payments and transfers of value to these healthcare providers under the Physician Payments Sunshine Act.
Sources:
Mink Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Mink Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Mink Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
